https://doi.org/10.55788/2db49d5b
Dr Lucas Overeem (Charité University Medicine Berlin, Germany) collected data from a retrospective, cross-sectional study including all patients who presented at the tertiary headache clinic between December 2015 and January 2023 [1]. Diagnoses were classified as self-reported by patients (based on their instructions from primary or secondary care doctors), diagnoses from a headache specialist (using doctor letters), and diagnoses according to the ICHD-3. Patients with missing doctor’s letters from lower levels or who had non-headache pain, such as facial pain or other syndromes, were excluded. In total, 1,468 patients were included in the analyses (75% women, mean age 43 years).
Overall, 97% of migraine diagnoses from the primary or secondary level of care were confirmed at the tertiary level of care; however, 32% of migraine diagnoses from the tertiary level of care were not provided at the primary or secondary levels of care. Furthermore, while 98% of migraine diagnoses from the primary or secondary level of care were confirmed using ICHD-3 criteria, 28% of the ICHD-3 criteria-diagnosed patients did not receive a correct diagnosis in primary or secondary care. The diagnosis concordance between the tertiary level of care and ICHD-3 criteria was 99%. Diagnostic criteria which were more likely to be missed at the primary or secondary level of care included aura, pain aggravation by physical activity, pain intensity of 6–9 on a visual analogue scale, nausea, vomiting, and photophobia.
“We found that migraine was underdiagnosed, tension-type headache overdiagnosed, and cluster headache underrecognised and misdiagnosed at the primary and secondary levels of care,” said Dr Overeem. “We identified that the absence of clinical criteria features led to misdiagnosis or missed diagnosis in lower levels of care, but it’s important to note that not all criteria always have to be fulfilled. We suggest that education and awareness improvement should continue, to help improve the diagnostic agreement.”
- Overeem LH, et al. Consistency between headache diagnoses and ICHD-3 criteria across different levels of care. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« PACAP-targeting therapies: a future option for migraine? Next Article
MRI analyses suggest that migraine is not associated with altered brain white matter »
« PACAP-targeting therapies: a future option for migraine? Next Article
MRI analyses suggest that migraine is not associated with altered brain white matter »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com